ViiV Healthcare presented positive interim data from the Phase III CARISEL study of Vocabria + Rekambys (cabotegravir + rilpivirine), which was initiated and conducted during the COVID-19 pandemic…. read more.
With low rates of disease flare and reactogenicity after vaccination, the study findings are reassuring for both patients and clinicians, according to Dr Caoilfhionn Connolly, Rheumatology Fellow at… read more.
A recent study at Johns Hopkins evaluated responses to SARS-CoV-2 vaccination in patients with rheumatoid and musculoskeletal disease (RMD)1 – a group that was poorly represented in the… read more.
Researchers at McMaster University have found that children who receive years of season-specific flu vaccines develop antibodies that also provide broader protection against new strains, including those capable… read more.
Multiple sclerosis (MS), a progressive disease that affects 2.8 million people worldwide and for which there is no definitive cure, is likely caused by infection with the Epstein-Barr… read more.
The drugs behind the new pills to treat COVID-19 remain very effective against the omicron variant of the virus in lab tests, according to a new study. However,… read more.
The European Medicines Agency (EMA) has authorised several new therapies and vaccines for COVID-19 which offer fresh hope of containing the two-year old pandemic, the EU drug watchdog… read more.
A new study, published in Nature Communications confirms what many people have suspected for a long time – namely that previous human coronavirus infection e.g. with the common cold, could… read more.
The threat of antimicrobial resistance (AMR), whereby antibiotics not longer work well on bacterial illness, is a slow-burning pandemic with the potential to eclipse even the worst of… read more.
Most people offered a COVID-19 vaccine in 2021 kept their appointment and rolled up their sleeves. However, as the year wore on, some countries struggled with vaccine hesitancy…. read more.
ViiV Healthcare, the global specialist HIV company majority-owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, has announced it has made a regulatory submission to the… read more.
Scientists at Scripps Research, University of Chicago and Icahn School of Medicine at Mount Sinai have identified a new Achilles’ heel of influenza virus, making progress in the… read more.
Advertisment
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
